Is ACADIA Pharmaceuticals Inc. (ACAD) a Buy, Sell, or Hold?
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$25.49 USD
-$0.01 (-0.04%)
- Volume
- 1.5M
- Average Volume
- 1.71M
- Market Capitalization
- $4.36B
- P/E Ratio
- 11.43
- Dividend Yield
- 0.00%
- Price Target
- $35.50
- Year High
- $28.35
- Year Low
- $19.69
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.59
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Catherine E. Owen Adams |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ACAD |
| CUSIP | 004225108 |
| CIK | 0001070494 |
| Web | https://www.acadia.com |
| Phone | 858 558 2871 |
| Currency | USD |
| Employees | 798 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.59 |
| Quick Ratio | 3.48 |
| Cash Ratio | 0.92 |
Sales & Book Value
| Annual Sales | $1.07B |
| Price / Sales | 3.99 |
| Cash Flow | 1.25 |
| Price / Cash Flow | 20.55 |
| Price / Book | 3.48 |
Price Target and Rating
| Average Stock Price Forecast | $35.50 |
| High Stock Price Forecast | $37.00 |
| Low Stock Price Forecast | $29.00 |
| Forecast Upside/Downside | -28.20% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 37 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.29 |
| Trailing P/E Ratio | 11.43 |
| PEG Ratio | 0.19 |
| P/E Growth | 0.19 |
| Net Income | $391M |
| Net Margin | 34.30% |
| Pretax Margin | 10.51% |
| Return on Equity | 35.65% |
| Return on Assets | 23.40% |
Financials Score
| AltmanZ Score | 7.29 |
| Piotroski Score | 4.00 |
| Working Capital | 790.49M |
| Total Assets | 1.61B |
| Ebit | 115.11M |
| Market Cap | 4.38B |
| Total Liabilities | 357.16M |
Poll Results
About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel ... synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
2026-07-11 16:50:01
Principal Accounting Officer James Kihara sold 11,421 shares for a transaction value of approximately ~$298,000 on June 26, 2026. The sale represented 46.60% of Kihara's direct holdings and reduced direct ownership to 13,088 shares.
RPRX or ACAD: Which Is the Better Value Stock Right Now?
2026-07-09 12:40:49
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
2026-07-06 09:04:00
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company's global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia's executive leadership team. “Carl is a proven global leader with a stro.
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
2026-06-29 12:16:06
Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus
2026-06-29 11:19:58
Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe. Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation. I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success.
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
2026-06-29 10:40:42
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy
2026-06-26 13:47:10
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares are trading higher on Friday as the company is celebrating a positive recommendation from the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) regarding its drug DAYBU (trofinetide) for treating neurobehavioral symptoms of Rett syndrome in the European Union.
Why Acadia Pharmaceuticals Stock Is Soaring Today
2026-06-26 12:17:59
Acadia Pharmaceuticals focuses on underserved rare diseases. Although they're (by definition) small markets, there's often little to no competition to treat rare and underserved diseases.
Frequently Asked Questions
-
What is the current ACADIA Pharmaceuticals Inc. (ACAD) stock price?
-
ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) stock price is $25.49 in the last trading session. During the trading session, ACAD stock reached the peak price of $28.35 while $19.69 was the lowest point it dropped to. The percentage change in ACAD stock occurred in the recent session was --0.04% while the dollar amount for the price change in ACAD stock was -$-0.01.
-
ACAD's industry and sector of operation?
-
The NASDAQ listed ACAD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ACAD?
-
Carl Segerstrom | Chief People Officer
Allyson McMillan Youngblood | Senior Vice President of Rare Disease Franchise
Scott Cenci | Senior Vice President, Chief Information & Data Officer
Thomas Andrew Garner | Executive Vice President & Chief Commercial Officer
Albert S. Kildani | Senior Vice President of Investor Relations & Corporate Communications -
How many employees does ACAD have?
-
Number of ACAD employees currently stands at 798. ACAD operates from 12830 El Camino Real, San Diego, CA 92130, US.
-
Link for ACAD official website?
-
Official Website of ACAD is: https://www.acadia.com
-
How do I contact ACAD?
-
ACAD could be contacted at phone #858 558 2871 and can also be accessed through its website. ACAD operates from 12830 El Camino Real, San Diego, CA 92130, US.
-
How many shares of ACAD are traded daily?
-
The average number of ACAD shares traded daily for last 3 months was 1.71M.
-
What is the market cap of ACAD currently?
-
The market value of ACAD currently stands at $4.36B with its latest stock price at $25.49